Salix Pays $2.6B For Santarus, Adding GI Offerings While Diversifying
This article was originally published in The Pink Sheet Daily
In a leveraged, all-cash deal, the North Carolina-based digestive disorder specialist Salix has acquired fast-growing Santarus, which has enjoyed a sales bump recently from diabetes treatment Glumetza.
You may also be interested in...
The onetime Celera CEO says his new attempt to centralize biological information into a massive database could lead to breakthroughs that extend the human life span. Behind that bold goal is a more mundane data-licensing strategy that, although not splashy, could still improve medicine.
Do high biotech share prices portend stock-heavy deal-making in lieu of all-cash transactions? Also, Biogen shares the risk with Eisai in an Alzheimer’s deal, while newly public Genocea and cell therapy specialist NeoStem both teamed with Harvard researchers.
When the IPO spigot runs dry, there’s M&A aplenty, and when the IPO wine is flowing, M&A slows down, right? FOTF tackles some conventional wisdom; plus deals from Acadia, Neurocrine, Aquinox, and Human Longevity.